CHEMICAL BIOLOGY-Oriented Targeted Therapeutics
Chemical Biology I Targeted Protein Degradation I Covalent Drug I Bioconjugation
Co-crystal structure of EGFR bound to JBJ-09-063
An allosteric inhibitor against the therapy- resistant mutant forms of EGFR in non-small cell lung cancer.
C To†, T S Beyett†, J Jang†, W W Feng, M Bahcall, H M Haikala, B H Shin, D E Heppner, J K Rana, B A Leeper, K M Soroko, M J Poitras, P C Gokhale, Y Kobayashi, K Wahid, K J Kurppa, T W Gero, M D Cameron, A Ogino, M Mushajiang, C Xu, Y Zhang, D A Scott, M J Eck, N S Gray, P A Jänne
Nature Cancer (2022) 3, 401-417.
Grapical abstract of the paper, Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations
Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations.
J Jang,† C To,† D J H De Clercq, E Park, C M Ponthier, B H Shin, M Mushajiang, R P Nowak, E S Fischer, M J Eck, P A Jänne,* N S Gray*
Angew. Chem. Int. Ed. (2020) 59, 14481–14489.
Grapical abstract of the paper, Visible‐Light‐Induced Cysteine‐Specific Bioconjugation: Biocompatible Thiol–Ene Click Chemistry
H Choi,† M Kim,† J Jang,* S Hong*
Angew. Chem. Int. Ed. (2020) 59, 22514-22522.
Grapical abstract of the paper, Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
C To,† J Jang,† T Chen, E Park, M Mushajiang, D J H De Clercq, M D Cameron, D E Heppner, A Yang, S E Dahlberg, K-K Wong, M J Eck, N S Gray,* P A Jänne*